What's in Duk-Woo Park, MD's pipeline?

Duk-Woo Park, MD has 4 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Duk-Woo Park, MD's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/duk-woo-park-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Duk-Woo Park, MD — Portfolio Competitive Intelligence Brief

Duk-Woo Park, MD pipeline: 3 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
P-CAB 50	P-CAB 50	marketed
Tailored antithrombotic strategy	Tailored antithrombotic strategy	marketed		Cardiovascular
Conventional antithrombotic strategy	Conventional antithrombotic strategy	marketed	Antithrombotic agents (antiplatelet and/or anticoagulant)	Cardiovascular

Therapeutic area mix

Cardiovascular · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Duk-Woo Park, MD:

Cite this brief

Drug Landscape (2026). Duk-Woo Park, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/duk-woo-park-md. Accessed 2026-05-16.